Organ-specific plasma proteome signatures reveal biological aging
PrimaryVero Bioscience's core causal theory is that age-related molecular changes in specific organs are reflected in circulating blood proteins with organ-specific signatures. By measuring thousands of plasma proteins and applying machine learning, the company claims it can estimate organ-level biological age from a single blood draw and detect early signs of organ aging before overt clinical disease appears. A testable prediction is that people whose OrganAge percentiles are high relative to age-matched peers should show higher future risk of organ-specific functional decline, age-related disease, or adverse clinical outcomes in the corresponding organ system. Conversely, people with lower or improving organ-age percentiles should show slower organ-specific deterioration or better longitudinal healthspan markers.
Popperian evaluation
The premise is biologically credible: organs shed, secrete, and regulate proteins that can appear in plasma, and aging changes tissue state. The weak point is specificity. A blood protein can move with inflammation, kidney clearance, liver production, medication use, or frailty without being a clean readout of one organ's aging process.
Supporting evidence: The theory starts from a plausible mechanism: age-related molecular changes in organs can affect circulating plasma proteins.; The proposed assay measures thousands of plasma proteins, which gives enough dimensionality to search for organ-linked patterns.; The reasoning graph correctly separates the core premise from the stronger assumption that these signatures are mechanistically tied to organ aging.
Counter evidence: The provided publications do not directly validate plasma proteomic OrganAge signatures for organ-specific biological aging.; The theory depends on the assumption that organ-specific signal can be separated from nonspecific health status, inflammation, disease burden, and clearance effects.; No cited evidence here shows that the measured proteins originate from, or causally track, the corresponding organ aging process.
The theory could explain why some people develop organ-linked decline earlier than age-matched peers, if high OrganAge percentiles predict future organ outcomes. On the evidence supplied here, that remains mostly a hypothesis. Alternative explanations are still live: the model may be detecting existing subclinical disease, systemic inflammation, kidney filtration changes, or general biological age rather than organ-specific aging.
Supporting evidence: The theory links one measurement, plasma proteomics, to a concrete clinical pattern: higher future risk in the matching organ system.; The OrganAge percentile concept gives a way to compare people against age-matched peers rather than raw chronological age.; The reasoning graph includes longitudinal predictions for functional decline, disease, adverse outcomes, and healthspan markers.
Counter evidence: The evidence context says the supporting publications do not directly report validation of plasma proteomic OrganAge signatures.; No longitudinal outcome data are provided showing that a high organ-age percentile predicts later decline in the same organ.; The theory has not yet ruled out broader correlates of poor health as the source of the signal.
This is testable. If people with high heart, kidney, brain, or liver OrganAge percentiles do not show higher future risk in those same organ systems after adjustment for age, sex, baseline disease, medication use, and standard biomarkers, the theory takes a direct hit. The strongest test is prospective: predict organ-specific decline before clinical disease appears, then check whether the forecast lands.
Supporting evidence: The theory makes a clear prediction: high OrganAge percentiles should predict higher future organ-specific functional decline.; It also predicts higher future risk of age-related disease and adverse clinical outcomes in the corresponding organ system.; It makes a directional counterprediction: lower or improving percentiles should track slower deterioration or better longitudinal healthspan markers.
Counter evidence: The prompt does not define exact effect-size thresholds, follow-up duration, organs, endpoints, or failure criteria.; Without prespecified outcomes and validation cohorts, machine-learning models can be tuned after the fact and look stronger than they are.; Improving organ-age percentiles could reflect assay variability or regression to the mean unless repeat testing is tightly controlled.
Reasoning tree
Public endorsements
The provided public quotes show Christin Glorioso discussing dementia risk, brain MRI self-tracking, lifestyle factors for brain health, diagnostics-plus-therapeutics strategy, and AI-matched continuous care. None of them mention Vero Bioscience's claim that organ-specific plasma proteome signatures can estimate organ-level biological age or predict organ-specific decline.
Okumus is publicly linked to organ-level biological age measurement through Teal Omics, and he is publicly credited with helping bring Vero Bioscience to life. That is a real public connection to the theory. What is missing is a direct public statement from him endorsing Vero's specific causal claim about organ-specific plasma proteome signatures, machine learning, or prediction of future organ decline from a blood draw.
Paul Coletta appears to publicly back the theory, not merely reference it. As Vero Bioscience's co-founder and CEO, he is tied to posts and company descriptions that say Vero measures biological age at the organ level, uses proteomics and AI, and aims to detect organ aging before disease appears. That matches the core claim closely enough to count as endorsement.
Evidence publication IDs: d2d4343b-8b2a-4e86-b89a-68bae1c7449d, a90612d3-04b7-498a-89b5-5e49558089f8, f37ead49-5949-4b6d-bdac-ef2b14f7d2a1, 48403072-bfe8-4a19-a999-8225aa54aa38
Wyss-Coray is publicly linked to the core claim that blood can reveal organ-specific biological age: the cited post says he measures in blood how old the heart and brain really are, with the goal of earlier disease detection. That matches the theory at a high level. The evidence stops short of a direct public endorsement from him of Vero's fuller causal framing about plasma proteomics, machine learning, and longitudinal risk prediction.